title: Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells.
abstract: Human adenovirus serotypes Ad3, Ad7, Ad11, and Ad14 use the epithelial junction protein desmoglein 2 (DSG2) as a receptor for infection. During Ad infection, the fiber and penton base capsid proteins are produced in vast excess and form hetero-oligomers, called pentons. It has been shown for Ad3 that pentons self-assemble into penton-dodecahedra (PtDd). Our previous studies with recombinant purified Ad3 PtDd (produced in insect cells) showed that PtDd bind to DSG2 and trigger intracellular signaling resulting in the transient opening of junctions between epithelial cells. So far, a definitive proof for a function of Ad3 PtDd in the viral life cycle is elusive. Based on the recently published 3D structure of recombinant Ad3 PtDd, we generated a penton base mutant Ad3 vector (mu-Ad3GFP). mu-Ad3GFP is identical to its wild-type counterpart (wt-Ad3GFP) in the efficiency of progeny virus production; however, it is disabled in the production of PtDd. For infection studies we used polarized epithelial cancer cells or cell spheroids. We showed that in wt-Ad3GFP infected cultures, PtDd were released from cells before viral cytolysis and triggered the restructuring of epithelial junctions. This in turn facilitated lateral viral spread of de novo produced virions. These events were nearly absent in mu-Ad3GFP infected cultures. Our in vitro findings were consolidated in mice carrying xenograft tumors derived from human epithelial cancer cells. Furthermore, we provide first evidence that PtDd are also formed by another DSG2-interacting Ad serotype, the newly emerged, highly pathogenic Ad14 strain (Ad14p1). The central finding of this study is that a subgroup of Ads has evolved to generate PtDd as a strategy to achieve penetration into and dissemination in epithelial tissues. Our findings are relevant for basic and applied virology, specifically for cancer virotherapy.
authors.affiliation: University of Washington, Division of Medical Genetics, Seattle, Washington, United States of America.
authors.forename: Zhuo-Zhuang
authors.initials: ZZ
authors.lastname: Lu
authors.forename: Hongjie
authors.initials: H
authors.lastname: Wang
authors.forename: Yiyi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Hua
authors.initials: H
authors.lastname: Cao
authors.forename: Zongyi
authors.initials: Z
authors.lastname: Li
authors.forename: Pascal
authors.initials: P
authors.lastname: Fender
authors.forename: André
authors.initials: A
authors.lastname: Lieber
mesh_terms: D000258:Adenovirus Infections, Human / Q000235:genetics / Q000378:metabolism / Q000635:transmission*; D000260:Adenoviruses, Human / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D004847:Epithelial Cells / Q000378:metabolism / Q000473:pathology / Q000821:virology*; D006367:HeLa Cells; D006801:Humans; D007365:Intercellular Junctions / Q000378:metabolism / Q000473:pathology / Q000821:virology*; D051379:Mice; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D050130:Oncolytic Virotherapy / Q000379:methods; D014771:Virion / Q000378:metabolism*